105 related articles for article (PubMed ID: 33129609)
1. Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.
Wolfe DN; Espeland EM; Gao Y; Lu D; Blatner G; Amass K; Horwith G; Tong XM; Hopkins R; David GL; Jepson BM; King JC
Vaccine; 2020 Nov; 38(50):7970-7976. PubMed ID: 33129609
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
[TBL] [Abstract][Full Text] [Related]
4. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
[TBL] [Abstract][Full Text] [Related]
5. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
Shearer JD; Henning L; Sanford DC; Li N; Skiadopoulos MH; Reece JJ; Ionin B; Savransky V
Vaccine; 2021 Jan; 39(1):1-5. PubMed ID: 33199078
[TBL] [Abstract][Full Text] [Related]
7. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.
Autumn Smiley M; Sanford DC; Triplett CA; Callahan D; Frolov V; Look J; Ruiz C; Reece JJ; Miles A; Ruiz E; Ionin B; Shearer JD; Savransky V
Vaccine; 2019 Oct; 37(43):6356-6361. PubMed ID: 31530467
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
Hopkins RJ; Howard C; Hunter-Stitt E; Kaptur PE; Pleune B; Muse D; Sheldon E; Davis M; Strout C; Vert-Wong K
Vaccine; 2014 Apr; 32(19):2217-24. PubMed ID: 24613523
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.
Rao VV; Godin CS; Lacy MJ; Inglefield JR; Park S; Blauth B; Reece JJ; Ionin B; Savransky V
Int J Toxicol; 2021 Oct; 40(5):442-452. PubMed ID: 34281421
[TBL] [Abstract][Full Text] [Related]
11. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
[TBL] [Abstract][Full Text] [Related]
12. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
[TBL] [Abstract][Full Text] [Related]
13. Developmental and reproductive safety evaluation of AV7909 anthrax vaccine candidate in rats.
Mylchreest E; Smiley MA; Ballin JD; Blauth B; Shearer J; Reece J; Ionin B; Savransky V
Birth Defects Res; 2021 Jan; 113(1):32-42. PubMed ID: 33067910
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults.
Schneider JC; Chen HC; Bautista E; Retallack D
Vaccine; 2021 Oct; 39(42):6333-6339. PubMed ID: 34544599
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.
Henning L; Anderson M; Triplett C; Smith T; Boyce K; Hendey L; Ridenour A; Eng J; Schaeufele D; Wilson E; Sabourin CL; Adams LE; Babas T; Parish L; Wolfe D
Hum Vaccin Immunother; 2023 Dec; 19(3):2290345. PubMed ID: 38115181
[TBL] [Abstract][Full Text] [Related]
16. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.
Bernstein DI; Jackson L; Patel SM; El Sahly HM; Spearman P; Rouphael N; Rudge TL; Hill H; Goll JB
Vaccine; 2014 Oct; 32(47):6284-93. PubMed ID: 25239484
[TBL] [Abstract][Full Text] [Related]
18. Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats.
Zmarowski A; Ballin JD; Sharits J; Carrico K; Novak J; Shearer J; Blauth B; Ionin B; Reece J; Savransky V
Int J Toxicol; 2020 Jul; ():1091581820941412. PubMed ID: 32691648
[TBL] [Abstract][Full Text] [Related]
19. Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
Perry MR; Ionin B; Barnewall RE; Vassar ML; Reece JJ; Park S; Lemiale L; Skiadopoulos MH; Shearer JD; Savransky V
Vaccine; 2020 Feb; 38(10):2307-2314. PubMed ID: 32029323
[TBL] [Abstract][Full Text] [Related]
20. Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule.
Longstreth J; Skiadopoulos MH; Hopkins RJ
Expert Rev Vaccines; 2016 Dec; 15(12):1467-1479. PubMed ID: 27792416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
